Epigenomics AG (EPGNF)

1.3300 0.0000 (0.00%) At close: 03:14PM EST

Epigenomics AG

Geneststrasse 5
Berlin 10829
Germany
49 30 243 450
https://www.epigenomics.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 36

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Gregory K. Hamilton	CEO & Member of the Exec. Board	859.52k	N/A	1970
Dr. Andrew A. Lukowiak Ph.D.	Pres & Chief Scientific Officer	401.98k	N/A	1972
Mr. Jens Ravens	CFO & Member of Exec. Board	N/A	N/A	1970
Frederic Hilke	Investor Relations Officer	N/A	N/A	N/A
Dr. Noel Thomas Doheny	Chief Exec. Officer of Epigenomics Inc.	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

Corporate Governance

Epigenomics AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.